Login Register Cart 0
Generic placeholder image

Current Cardiology Reviews

Editor-in-Chief

ISSN (Print): 1573-403X
ISSN (Online): 1875-6557

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Ignored Role of Paroxysmal Atrial Fibrillation in the Pathophysiology of Cryptogenic Stroke in Patients with Patent Foramen Ovale and Atrial Septal Aneurysm

Author(s): Ertan Yetkin*, Hasan Atmaca, Bilal Çuğlan and Kenan Yalta

Volume 20, Issue 2, 2024

Published on: 01 February, 2024

Article ID: e010224226635 Pages: 6

DOI: 10.2174/011573403X267669240125041203

Price: $65

Abstract

The association between cryptogenic stroke (CS) and patent foramen ovale (PFO) with or without atrial septal aneurysm (ASA) has been a debate for decades in terms of pathophysiologic processes and clinical courses. This issue has become more interesting and complex, because of the concerns associating the CS with so-called normal variant pathologies of interatrial septum, namely ASA and PFO. While there is an anatomical pathology in the interatrial septum, namely PFO and ASA, the embolic source of stroke is not clearly defined. Moreover, in patients with PFO and CS, the risk of recurrent stroke has also been associated with other PFOunrelated factors, such as hyperlipidemia, body mass index, diabetes mellitus, and hypertension, leading to the difficulty in understanding the pathophysiologic mechanism of CS in patients with PFO and/or ASA. Theoretically, the embolic source of cryptogenic stroke in which PFO and/or ASA has been involved can be categorized into three different anatomical locations, namely PFO tissue and/or ASA tissue itself, right or left atrial chambers, and venous vascular territory distal to the right atrium, i.e., inferior vena cava and lower extremity venous system. However, the possible role of paroxysmal atrial fibrillation associated with PFO and/or ASA as a source of cryptogenic stroke has never been mentioned clearly in the literature. This review aims to explain the association of cryptogenic stroke with PFO and/or ASA in a comprehensive manner, including anatomical, clinical, and mechanistic aspects.

The potential role of paroxysmal atrial fibrillation and its contribution to clinical course have been also discussed in a hypothetical manner to elucidate the pathophysiology of CS and support further treatment modalities.

Keywords: Stroke, cryptogenic stroke, atrial septal aneurysm, patent foramen ovale, atrial fibrillation, pathophysiology.

Graphical Abstract

[1]
Kuriki A, Ueno Y, Kamiya Y, et al. Atrial septal aneurysm may cause in-hospital recurrence of cryptogenic stroke. J Atheroscler Thromb 2021; 28(5): 514-23.
[http://dx.doi.org/10.5551/jat.56440] [PMID: 32684557]
[2]
Hart RG, Catanese L, Perera KS, Ntaios G, Connolly SJ. Embolic stroke of undetermined source. Stroke 2017; 48(4): 867-72.
[http://dx.doi.org/10.1161/STROKEAHA.116.016414] [PMID: 28265016]
[3]
Hart RG, Diener HC, Coutts SB, et al. Embolic strokes of undetermined source: The case for a new clinical construct. Lancet Neurol 2014; 13(4): 429-38.
[http://dx.doi.org/10.1016/S1474-4422(13)70310-7] [PMID: 24646875]
[4]
Leonard Y, Marras M, Calcaterra G, et al. Association between atrial septal abnormalities (patent foramen ovale, atrial septal defect, interatrial septal aneurysm) and cryptogenic stroke in children. J Pediatric Neonatal Individ Med 2021; 10(1): e100154-4. [JPNIM].
[5]
Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: A meta-analysis of case-control studies. Neurology 2000; 55(8): 1172-9.
[http://dx.doi.org/10.1212/WNL.55.8.1172] [PMID: 11071496]
[6]
Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: An autopsy study of 965 normal hearts. Mayo Clin Proc 1984; 59(1): 17-20.
[http://dx.doi.org/10.1016/S0025-6196(12)60336-X] [PMID: 6694427]
[7]
Meissner I, Whisnant JP, Khandheria BK, et al. Prevalence of potential risk factors for stroke assessed by transesophageal echocardiography and carotid ultrasonography: The SPARC study. Stroke prevention: Assessment of risk in a community. Mayo Clin Proc 1999; 74(9): 862-9.
[http://dx.doi.org/10.4065/74.9.862] [PMID: 10488786]
[8]
Hara H, Virmani R, Ladich E, et al. Patent foramen ovale: Current pathology, pathophysiology, and clinical status. J Am Coll Cardiol 2005; 46(9): 1768-76.
[http://dx.doi.org/10.1016/j.jacc.2005.08.038] [PMID: 16256883]
[9]
Mas JL, Derumeaux G, Guillon B, et al. Patent foramen ovale closure or anticoagulation vs. Antiplatelets after stroke. N Engl J Med 2017; 377(11): 1011-21.
[http://dx.doi.org/10.1056/NEJMoa1705915] [PMID: 28902593]
[10]
Søndergaard L, Kasner SE, Rhodes JF, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med 2017; 377(11): 1033-42.
[http://dx.doi.org/10.1056/NEJMoa1707404] [PMID: 28902580]
[11]
Yetkin E, Atalay H, Ileri M. Atrial septal aneurysm: Prevalence and covariates in adults. Int J Cardiol 2016; 223: 656-9.
[http://dx.doi.org/10.1016/j.ijcard.2016.08.220] [PMID: 27567234]
[12]
Mattioli A, Aquilina M, Oldani A, Longhini C, Mattioli G. Atrial septal aneurysm as a cardioembolic source in adult patients with stroke and normal carotid arteries. A multicentre study. Eur Heart J 2001; 22(3): 261-8.
[http://dx.doi.org/10.1053/euhj.2001.2293] [PMID: 11161938]
[13]
Rigatelli G, Zuin M, Bilato C. Atrial septal aneurysm contribution to the risk of cryptogenic stroke in patients with patent foramen ovale: A brief updated systematic review and meta-analysis. Trends Cardiovasc Med 2023; 33(6): 329-33.
[http://dx.doi.org/10.1016/j.tcm.2022.02.006] [PMID: 35181471]
[14]
Beelke M, Angeli S, del Sette M, et al. Obstructive sleep apnea can be provocative for right-to-left shunting through a patent foramen ovale. Sleep 2002; 25(8): 21-7.
[http://dx.doi.org/10.1093/sleep/25.8.21] [PMID: 12489891]
[15]
Fisher DC, Fisher EA, Budd JH, Rosen SE, Goldman ME. The incidence of patent foramen ovale in 1,000 consecutive patients. A contrast transesophageal echocardiography study. Chest 1995; 107(6): 1504-9.
[http://dx.doi.org/10.1378/chest.107.6.1504] [PMID: 7781337]
[16]
Webster MWI, Smith HJ, Sharpe DN, et al. Patent foramen ovale in young stroke patients. Lancet 1988; 332(8601): 11-2.
[http://dx.doi.org/10.1016/S0140-6736(88)92944-3] [PMID: 2898621]
[17]
Scharf SM. Influence of sleep state and breathing on cardiovascular function. In: Saunders NA, Sullivan CE, Eds. Sleep and breathing: lung biology in health and disease. (1st ed.). New York: Marvel Dekker Inc 1984; Vol. 21: pp. 221-40.
[18]
Ghosh S, Ghosh AK, Ghosh SK. Patent foramen ovale and atrial septal aneurysm in cryptogenic stroke. Postgrad Med J 2007; 83(977): 173-7.
[http://dx.doi.org/10.1136/pgmj.2006.051094] [PMID: 17344571]
[19]
Ghafoor H, Sharma NK, Hashmath Z, Ramsaran E. Peripheral thrombosis causing simultaneous saddle pulmonary embolism and paradoxical ST elevation myocardial infarction resulting in cardiovascular collapse. BMJ Case Rep 2021; 14(4): e240312.
[http://dx.doi.org/10.1136/bcr-2020-240312] [PMID: 33883112]
[20]
Suraci N, Galtes I, Presti S, Santana O. Thrombus in transit across a patent foramen ovale in a patient with cerebrovascular accidents, pulmonary embolism, and deep vein thrombosis. Ann Card Anaesth 2021; 24(3): 362-4.
[http://dx.doi.org/10.4103/aca.ACA_120_19] [PMID: 34269269]
[21]
Banana Y, Rezziki A, Kallel O, et al. Multiple paradoxical embolisms revealing a patent foramen ovale in a patient with deep venous thrombosis: A case report. Ann Med Surg 2021; 66: 102426.
[http://dx.doi.org/10.1016/j.amsu.2021.102426] [PMID: 34141413]
[22]
Kass M, Grocott HP, Shah AH. Constellation of stroke, pulmonary embolism, and platypnea orthodeoxia syndrome. JACC Cardiovasc Interv 2021; 14(14): e165-7.
[http://dx.doi.org/10.1016/j.jcin.2021.03.034] [PMID: 34217629]
[23]
Saunders H, Al Khalifa A, Espinosa A, Jain M. Massive pulmonary embolism and thrombus-in-transit via a patent foramen ovale: A case report of successful use of extracorporeal membrane oxygenation to manage post-embolectomy severe right ventricular dysfunction. Eur Heart J Case Rep 2021; 5(4): ytab100.
[http://dx.doi.org/10.1093/ehjcr/ytab100] [PMID: 34124547]
[24]
Nuñez R, Sanchez JA, Berber S, et al. Case report: Thrombus in transit—a cause of impending paradoxical embolism. Eur Heart J Case Rep 2021; 5(2): ytaa580.
[http://dx.doi.org/10.1093/ehjcr/ytaa580] [PMID: 33738414]
[25]
Yetkin E, Ileri M, Korkmaz A, Ozturk S. Association between atrial septal aneurysm and arrhythmias. Scand Cardiovasc J 2020; 54(3): 169-73.
[http://dx.doi.org/10.1080/14017431.2019.1667525] [PMID: 31544553]
[26]
Atak R, Ileri M, Ozturk S, Korkmaz A, Yetkin E. Echocardiographic findings in patients with atrial septal aneurysm: A prospective case-control study. Cardiol Res Pract 2019; 2019: 1-7.
[http://dx.doi.org/10.1155/2019/3215765] [PMID: 31061729]
[27]
Yetkin E, Atmaca H, Cuglan B, Yalta K. atrial septal aneurysm cryptogenic stroke: An arrhythmic approach to pathophysiology. J Pediatric Neonatal Individ Med 2021. In press
[28]
Janion M, Kurzawski J. Atrial fibrillation in patients with atrial septal aneurysm. Cardiol J 2007; 16(6): 580-4. ASAS5
[29]
Agmon Y, Khandheria BK, Meissner I, et al. Frequency of atrial septal aneurysms in patients with cerebral ischemic events. Circulation 1999; 99(15): 1942-4.
[http://dx.doi.org/10.1161/01.CIR.99.15.1942] [PMID: 10208995]
[30]
Furlan AJ, Reisman M, Massaro J, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med 2012; 366(11): 991-9.
[http://dx.doi.org/10.1056/NEJMoa1009639] [PMID: 22417252]
[31]
Meier B, Kalesan B, Mattle HP, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med 2013; 368(12): 1083-91.
[http://dx.doi.org/10.1056/NEJMoa1211716] [PMID: 23514285]
[32]
Dowson A, Mullen MJ, Peatfield R, et al. Migraine intervention with STARFlex technology (MIST) trial: A prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache. Circulation 2008; 117(11): 1397-404.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.107.727271] [PMID: 18316488]
[33]
Turc G, Lee JY, Brochet E, Kim JS, Song JK, Mas JL. CLOSE and DEFENSE-PFO trial investigators. Atrial septal aneurysm, shunt size, and recurrent stroke risk in patients with patent foramen ovale. J Am Coll Cardiol 2020; 75(18): 2312-20.
[34]
Reiffel JA, Verma A, Kowey PR, et al. Incidence of previously undiagnosed atrial fibrillation using insertable cardiac monitors in a high-risk population. JAMA Cardiol 2017; 2(10): 1120-7.
[http://dx.doi.org/10.1001/jamacardio.2017.3180] [PMID: 28842973]
[35]
Healey JS, Alings M, Ha A, et al. Subclinical atrial fibrillation in older patients. Circulation 2017; 136(14): 1276-83.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.117.028845] [PMID: 28778946]
[36]
Nasir JM, Pomeroy W, Marler A, et al. Predicting determinants of atrial fibrillation or flutter for therapy elucidation in patients at risk for thromboembolic events (PREDATE AF) study. Heart Rhythm 2017; 14(7): 955-61.
[http://dx.doi.org/10.1016/j.hrthm.2017.04.026] [PMID: 28506913]
[37]
Svendsen JH, Diederichsen SZ, Højberg S, et al. Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): A randomised controlled trial. Lancet 1507; 398(10310): 1507-16.
[38]
Elsheikh S, Lip GYH, Abdul-Rahim AH, et al. Potential embolic sources in embolic stroke of undetermined source in patients with patent foramen ovale: Look harder. Cerebrovasc Dis 2023; 1-2.
[http://dx.doi.org/10.1159/000529105] [PMID: 36750045]
[39]
Kahles T, Michel P, Hapfelmeier A, et al. Prior stroke in PFO patients is associated with both PFO-related and -unrelated factors. Front Neurol 2020; 11: 503.
[http://dx.doi.org/10.3389/fneur.2020.00503] [PMID: 32582015]
[40]
Carroll JD, Saver JL, Thaler DE, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med 2013; 368(12): 1092-100.
[http://dx.doi.org/10.1056/NEJMoa1301440] [PMID: 23514286]
[41]
Lee PH, Song JK, Kim JS, et al. Cryptogenic stroke and high-risk patent foramen ovale. J Am Coll Cardiol 2018; 71(20): 2335-42.
[http://dx.doi.org/10.1016/j.jacc.2018.02.046] [PMID: 29544871]
[42]
Saver JL, Carroll JD, Thaler DE, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med 2017; 377(11): 1022-32.
[http://dx.doi.org/10.1056/NEJMoa1610057] [PMID: 28902590]
[43]
Pan X, Xu L, Zhou C, et al. Meta-analysis of patent foramen ovale closure versus medical therapy for prevention of recurrent ischemic neurological events: Impact of medication type. Medicine 2021; 100(25): e26473.
[44]
Saver JL, Mattle HP, Thaler D. Patent foramen ovale closure versus medical therapy for cryptogenic ischemic stroke. Stroke 2018; 49(6): 1541-8.
[http://dx.doi.org/10.1161/STROKEAHA.117.018153] [PMID: 29760277]
[45]
Turc G, Calvet D, Guérin P, Sroussi M, Chatellier G, Mas JL. Closure, anticoagulation, or antiplatelet therapy for cryptogenic stroke with patent foramen ovale: Systematic review of randomized trials, sequential meta‐analysis, and new insights from the CLOSE study. J Am Heart Assoc 2018; 7(12): e008356.
[http://dx.doi.org/10.1161/JAHA.117.008356] [PMID: 29910193]

Rights & Permissions Print Cite
Article Metrics
15
1
© 2024 Bentham Science Publishers | Privacy Policy